ArticleClinical ophthalmology (Auckland, N.Z.)2016
Tear lipid layer thickness with eye drops in meibomian gland dysfunction.
Article in Clinical ophthalmology (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Effects of HP-Guar Nano-emulsion Artificial Tears on Symptoms and Severity of Meibomian Gland Dysfunction in Evaporative Dry Eye During a 90-Day Longitudinal Study.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Trial
- To assess the effectiveness of Systane COMPLETE in improving meibomian gland score and in reducing symptoms of ocular dryness.Frontiers in ophthalmology · 2025Article
- Hyaluronic Acid and Galacto-Xyloglucan Eyedrop Efficacy in Young-Adult Oral Contraceptive Users of Childbearing Age.Journal of clinical medicine · 2022Article
- Lipid, Aqueous and Mucin Tear Film Layer Stability and Permanence within 0.15% Liposome Crosslinked Hyaluronic Acid versus 0.15% Non-Crosslinked Hyaluronic Acid Measured with a Novel Non-Invasive Ocular Surface Analyzer.Journal of clinical medicine · 2022Article
- Oral isotretinoin for acne vulgaris side effects on the ocular surface: Hyaluronic acid and galacto-xyloglucan as treatment for dry eye disease signs and symptoms.Frontiers in medicine · 2022Article
- Novel Approaches for Imaging-Based Diagnosis of Ocular Surface Disease.Diagnostics (Basel, Switzerland) · 2020Review
- Short-Term Changes in Tear Lipid Layer Thickness After Instillation of Lipid Containing Eye Drops.Translational vision science & technology · 2020Article
- Comparison of meibomian gland loss area measurements between two computer programs and intra-inter-observer agreement.International ophthalmology · 2020Observational
- A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Dry Eye Disease: Emerging Approaches to Disease Analysis and Therapy.Journal of clinical medicine · 2019Review
- Changes in Tear Lipid Layer Thickness and Symptoms Following the Use of Artificial Tears with and Without Omega-3 Fatty Acids: A Randomized, Double-Masked, Crossover Study.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- Low concentration of sodium hyaluronate temporarily elevates the tear film lipid layer thickness in dry eye patients with lipid deficiency.International journal of ophthalmology · 2018Article
- Surface Chemistry Interactions of Cationorm with Films by Human Meibum and Tear Film Compounds.International journal of molecular sciences · 2017Article
- Evaluation of lipid layer tear film changes after femtosecond small incision lenticule extraction.Therapeutic advances in ophthalmologyArticle
- Comparison of nanoemulsion and non-emollient artificial tears on tear lipid layer thickness and symptoms.Journal of optometryObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate the efficacy of a lipid containing emollient eye drop, Soothe XP, which was reformulated in 2014 with a more stable preservative and buffer system, compared to a control, non-emollient, eye drop (Systane Ultra) in improving lipid layer thickness (LLT) in subjects with dry eye due to meibomian gland dysfunction (MGD). PATIENTS AND
methodsThis prospective single-center, open-label, cross-over, examiner masked-study enrolled subjects aged 30-75 years with lipid-deficient dry eye and a clinical diagnosis of MGD as determined by a slit lamp examination, an evaluation of meibomian gland drop out with meibography, and a standard patient evaluation of eye dryness questionnaire of >5. Eligibility was then determined by a LLT of <75 nm at baseline and the inability to increase LLT ≥15 nm with three blinks, as determined by interferometric methods. Subjects were randomized to receive a single emollient or non-emollient eye drop at Visit 1 and were crossed over for the alternate treatment at Visit 2. At each visit, LLT was measured prior to and 15 minutes following the instillation of the assigned eye drop. The primary endpoint was the change in LLT from baseline.
resultsSubjects (n=40) were enrolled and 35 completed the two study arms. Mean (±SD) patient age was 55.7 years (10.9) and 69% were female. Mean (±SD) LLT at baseline was 49.5 nm (9.2). Instillation of Soothe XP resulted in an increase in LLT to 77.5 nm (29.3) 15 minutes following drop instillation, which is an increase of 28.0 nm (27.4) (
conclusionIn this study of subjects with MGD, the emollient, or lipid containing eye drop, increased the LLT of tears when measured 15 minutes after instilling a single eye drop.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.